PMID- 10747834
OWN - NLM
STAT- MEDLINE
DCOM- 20000711
LR  - 20190513
IS  - 0305-7453 (Print)
IS  - 0305-7453 (Linking)
VI  - 45
IP  - 4
DP  - 2000 Apr
TI  - Endothelial cell compatibility of trovafloxacin and levofloxacin for intravenous 
      use.
PG  - 533-5
AB  - Levofloxacin and trovafloxacin have excellent activity against a variety of 
      Gram-positive and Gram-negative organisms resistant to the established agents. 
      One local side-effect closely related to the use of parenteral fluoroquinolones 
      is phlebitis. To evaluate the effect of trovafloxacin and levofloxacin on 
      endothelial cell viability, intracellular levels of adenosine 5'-triphosphate 
      (ATP), adenosine 5'-diphosphate (ADP), guanosine 5'-triphosphate (GTP) and 
      guanosine 5'-diphosphate (GDP) levels were measured using high-performance liquid 
      chromatography. Trovafloxacin at concentrations of 2 and 1 mg/mL reduced the 
      intracellular ATP content from 12.5 +/- 1.7 to 1.9 +/- 0.3 nmol/10(6) cells and 
      9.3 +/- 0.8 nmol/10(6) cells, respectively, within 60 min. In addition, ADP, GTP 
      and GDP levels were extensively depleted. Levofloxacin at concentrations of 5 and 
      2.5 mg/mL led to a significant ATP decline from 12.5 +/- 1.7 to 2.3 +/- 0.2 
      nmol/10(6) cells and 10.3 +/- 0.9 nmol/10(6) cells, respectively, within 60 min. 
      These data indicate that infusions of high doses of trovafloxacin or levofloxacin 
      are not compatible with maintenance of endothelial cell function. Commercial 
      preparations have to be diluted and should be administered into large veins.
FAU - Armbruster, C
AU  - Armbruster C
AD  - Second Medical Department/Pulmologisches Zentrum Vienna, Austria.
FAU - Robibaro, B
AU  - Robibaro B
FAU - Griesmacher, A
AU  - Griesmacher A
FAU - Vorbach, H
AU  - Vorbach H
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Culture Media)
RN  - 0 (Fluoroquinolones)
RN  - 0 (Naphthyridines)
RN  - 146-91-8 (Guanosine Diphosphate)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 6GNT3Y5LMF (Levofloxacin)
RN  - 86-01-1 (Guanosine Triphosphate)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - 9F388J00UK (trovafloxacin)
RN  - A4P49JAZ9H (Ofloxacin)
SB  - IM
MH  - Adenosine Diphosphate/metabolism
MH  - Adenosine Triphosphate/metabolism
MH  - Anti-Infective Agents/administration & dosage/*toxicity
MH  - Cell Survival/drug effects
MH  - Chromatography, High Pressure Liquid
MH  - Culture Media
MH  - Endothelium, Vascular/*cytology/*drug effects
MH  - Female
MH  - *Fluoroquinolones
MH  - Guanosine Diphosphate/metabolism
MH  - Guanosine Triphosphate/metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - *Levofloxacin
MH  - Naphthyridines/administration & dosage/*toxicity
MH  - Ofloxacin/administration & dosage/*toxicity
MH  - Pregnancy
MH  - Umbilical Veins/cytology/drug effects
EDAT- 2000/04/05 09:00
MHDA- 2000/07/15 11:00
CRDT- 2000/04/05 09:00
PHST- 2000/04/05 09:00 [pubmed]
PHST- 2000/07/15 11:00 [medline]
PHST- 2000/04/05 09:00 [entrez]
AID - 10.1093/jac/45.4.533 [doi]
PST - ppublish
SO  - J Antimicrob Chemother. 2000 Apr;45(4):533-5. doi: 10.1093/jac/45.4.533.